We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+9.63%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$59.8B
AUM Growth
+$5.07B
(+9.3%)
Cap. Flow
+$518M
Cap. Flow
% of AUM
0.87%
Top 10 Holdings %
Top 10 Hldgs %
18.08%
Holding
2,992
New
38
Increased
2,358
Reduced
537
Closed
43
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$68M |
| 2 |
Truist Financial
TFC
|
+$55.9M |
| 3 |
ServiceNow
NOW
|
+$33.3M |
| 4 |
Uber
UBER
|
+$21.4M |
| 5 |
Las Vegas Sands
LVS
|
+$15.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$119M |
| 2 |
STI
SunTrust Banks, Inc.
STI
|
+$55.9M |
| 3 |
Apple
AAPL
|
+$48.3M |
| 4 |
iShares TIPS Bond ETF
TIP
|
+$22M |
| 5 |
VIAB
Viacom Inc. Class B
VIAB
|
+$16.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Financials | 15.53% |
| 3 | Healthcare | 13.38% |
| 4 | Consumer Discretionary | 10.07% |
| 5 | Industrials | 9.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
RUBY
2426
DELISTED
Rubius Therapeutics, Inc
RUBY
| $431K | ﹤0.01% |
45,362
+304
| +0.7% | +$2.94K |
|
|
ORBC
2427
DELISTED
ORBCOMM, Inc.
ORBC
| $431K | ﹤0.01% |
102,380
-559
| -0.5% | -$2.39K |
|
|
EIGI
2428
DELISTED
Endurance International Group Holdings, Inc.
EIGI
| $430K | ﹤0.01% |
91,433
+842
| +0.9% | +$3.46K |
|
2429
Napco Security Technologies
NSSC
$1.44B
| $429K | ﹤0.01% |
29,160
+348
| +1% | +$5.05K |
|
2430
The RealReal
REAL
$1.52B
| $429K | ﹤0.01% |
22,742
+3,735
| +20% | +$71.5K |
|
|
AMK
2431
DELISTED
AssetMark Financial Holdings, Inc.
AMK
| $429K | ﹤0.01% |
14,766
+487
| +3% | +$12.7K |
|
2432
Western New England Bancorp
WNEB
$280M
| $428K | ﹤0.01% |
44,397
-188
| -0.4% | -$1.82K |
|
2433
Alpha and Omega Semiconductor
AOSL
$974M
| $426K | ﹤0.01% |
31,313
+348
| +1% | +$4.4K |
|
2434
Inovio Pharmaceuticals
INO
$69.7M
| $425K | ﹤0.01% |
10,720
+441
| +4% | +$13.3K |
|
2435
Global Industrial
GIC
$1.48B
| $424K | ﹤0.01% |
16,838
+161
| +1% | +$3.75K |
|
|
SCU
2436
DELISTED
Sculptor Capital Management, Inc. Class A Common Stock
SCU
| $424K | ﹤0.01% |
19,179
+171
| +0.9% | +$3.17K |
|
2437
Bank First Corp
BFC
$1.73B
| $422K | ﹤0.01% |
6,034
+142
| +2% | +$9.7K |
|
2438
Global Indemnity Group
GBLI
$414M
| $422K | ﹤0.01% |
14,244
-13
| -0.1% | -$346 |
|
|
BCOV
2439
DELISTED
Brightcove, Inc.
BCOV
| $421K | ﹤0.01% |
48,446
+403
| +0.8% | +$3.78K |
|
2440
Omega Flex
OFLX
$306M
| $417K | ﹤0.01% |
3,891
+100
| +3% | +$9.75K |
|
2441
Oppenheimer Holdings
OPY
$1.24B
| $417K | ﹤0.01% |
15,157
+141
| +0.9% | +$3.93K |
|
2442
Clarus
CLAR
$130M
| $416K | ﹤0.01% |
30,806
-516
| -2% | -$6.36K |
|
2443
Franklin Covey
FC
$247M
| $416K | ﹤0.01% |
12,920
+48
| +0.4% | +$1.74K |
|
2444
Forestar Group
FOR
$1.51B
| $415K | ﹤0.01% |
19,905
+671
| +3% | +$13.1K |
|
2445
Inseego
INSG
$121M
| $415K | ﹤0.01% |
5,663
+614
| +12% | +$35.4K |
|
2446
Intrepid Potash
IPI
$453M
| $415K | ﹤0.01% |
15,317
-121
| -0.8% | -$3.29K |
|
|
GNTY
2447
DELISTED
Guaranty Bancshares
GNTY
| $413K | ﹤0.01% |
13,815
-54
| -0.4% | -$1.57K |
|
2448
Willdan Group
WLDN
$1.12B
| $413K | ﹤0.01% |
12,990
+108
| +0.8% | +$3.42K |
|
|
PFNX
2449
DELISTED
Pfenex Inc.
PFNX
| $413K | ﹤0.01% |
37,594
+299
| +0.8% | +$2.97K |
|
|
LVGO
2450
DELISTED
Livongo Health, Inc. Common Stock
LVGO
| $412K | ﹤0.01% |
16,432
+2,793
| +20% | +$66.8K |
|
Similar funds
VAM
RhumbLine Advisers's Q4 2019 Portfolio in Review
As of Q4 2019, RhumbLine Advisers held 2,992 positions worth $59.8B, up 9.3% from $54.7B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Trading was light in Q4 2019: portfolio turnover was 2.7%. RhumbLine Advisers opened 38 new positions and exited 43, leaving the 2,992-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q4 2019 buy was Envista: 126,664 shares worth $3.75M.
- RhumbLine Advisers added most to Bristol-Myers Squibb in Q4 2019, an estimated $68M increase.
- RhumbLine Advisers's biggest Q4 2019 reduction was Apple, cutting an estimated $48.3M.
- RhumbLine Advisers fully exited Celgene Corp in Q4 2019, selling an estimated $119M.
- RhumbLine Advisers's ten largest holdings make up 18% of its $59.8B portfolio in Q4 2019.
- RhumbLine Advisers opened 38 new positions and closed 43 in Q4 2019.
- RhumbLine Advisers's portfolio value rose 9.3% quarter-over-quarter to $59.8B.
Based on RhumbLine Advisers's 13F filing for Q4 2019, filed 5 Feb 2020.